KLRA

Kailera Therapeutics, Inc. Common Stock

KLRA.US kailera.com + Research + Basket
Employees 145
Phone 781 317 0290
Fiscal year end December
IPO Apr 17, 2026
Address 180 Third Avenue, Waltham, MA, United States, 02451
13.12
-0.02 (-0.11%)
USD · NASDAQ
52-week range
9.76
28.23
Trading at 18% of the 52-week range
Market Cap
1.70B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
8.63
Div. Yield
N/A
% Institutions
90.45%
% Insiders
8.91%

1 Year

-17.9%

3 Year

-17.9%

10 Year

-17.9%
Description

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Actions

Add an action for KLRA.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Ronald C. Renaud Jr., M.B.A. President, CEO & Director 1969
Mr. Paul Douglas Burgess J.D., M.S. Chief Operating & Business Officer 1974
Ms. Jamie Beth Coleman Chief Commercial Officer 1978
Mr. Douglas W. Pagan M.B.A. Chief Financial Officer 1972
Maura Gavaghan Vice President of Corporate Communications & Investor Relations NA
Mr. Scott M. Akamine J.D. Chief Legal Officer & Secretary 1985
Ms. Paula A. Cloghessy SHRM-SCP, SPHR Chief People Officer 1972
Dr. Scott M. Wasserman M.D. Chief Medical Officer 1970
Ms. Kathleen Tregoning M.A. Chief Corporate Affairs Officer 1971
Mr. Corey Manchester Treasurer NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 20, 2026 Adam Koppel N/A Purchase 1.56M $16.00 $25.00M SEC
Apr 20, 2026 Andrew T Kaplan N/A Purchase 8.40M $16.00 $134.38M SEC
Apr 20, 2026 Rtw Investments, Lp N/A Purchase 500.00K $16.00 $8.00M SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Bain Capital Investors LLC 26.26M Jun 30, 2026 20.25% $12.01 0.00%
Bain Capital Life Sciences Investors, LLC 22.58M Jun 30, 2026 17.42% $29.58 0.00%
RTW INVESTMENTS, LLC 10.78M Jun 30, 2026 8.31% $2.03 0.00%
Canada Pension Plan Investment Board 7.30M Jun 30, 2026 5.63% $0.09 0.00%
Atlas Venture Life Science Advisors, LLC 5.17M Jun 30, 2026 3.99% $12.93 0.00%
FMR Inc 3.97M Jun 30, 2026 3.06% $0.00 0.00%
BlackRock Inc 3.93M Jun 30, 2026 3.03% $0.00 0.00%
T. Rowe Price Associates, Inc. 3.53M Jun 30, 2026 2.73% $0.01 0.00%
Citadel Advisors Llc 3.24M Jun 30, 2026 2.50% $0.01 0.00%
Adage Capital Partners Gp LLC 3.21M Jun 30, 2026 2.47% $0.10 0.00%
Wellington Management Company LLP 2.92M Jun 30, 2026 2.25% $0.01 0.00%
Royalty Pharma Sub-Manager, LLC 2.46M Jun 30, 2026 1.89% $22.36 0.00%
Siren, L.L.C. 2.21M Jun 30, 2026 1.71% $0.99 0.00%
Vanguard Capital Management, LLC 1.69M Jun 30, 2026 1.31% $0.00 0.00%
Vanguard Portfolio Management, LLC 1.65M Jun 30, 2026 1.27% $0.00 0.00%
Geode Capital Management, LLC 1.13M Jun 30, 2026 0.87% $0.00 0.00%
Frazier Life Sciences Management, L.P. 1.10M Jun 30, 2026 0.85% $0.53 0.00%
Farallon Capital Management, L.L.C. 1.10M Jun 30, 2026 0.85% $0.11 0.00%
Trails Edge Capital Partners, LP 984.79K Jun 30, 2026 0.76% $3.44 0.00%
UBS Group AG 972.68K Jun 30, 2026 0.75% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Health Care Inv 2.19M 1.69% ▲ 0.00% Jun 30, 2026
2 State Street® SPDR® S&P® Biotech ETF 1.23M 0.95% ▼ 1.88% Sep 30, 2026
3 iShares Russell 2000 ETF 1.20M 0.93% ▼ 1.14% Sep 30, 2026
4 Vanguard MStar Total Stk Mkt Idx Invest 1.18M 0.91% ▲ 0.00% Sep 30, 2026
5 Vanguard Small Cap Index 835.57K 0.64% ▼ 2.08% Sep 30, 2026
6 Columbia Small Cap Growth Inst 784.06K 0.60% ▲ 0.00% Aug 31, 2026
7 Fidelity Growth Company Fund 700.90K 0.54% ▲ 0.00% Aug 31, 2026
8 Fidelity Select Biotechnology 632.00K 0.49% ▲ 0.85% Aug 31, 2026
9 T. Rowe Price Health Sciences 626.70K 0.48% ▼ 42.78% Sep 30, 2026
10 Eventide Healthcare & Life Sciences I 616.72K 0.48% ▲ 0.00% Jun 30, 2026

Financial Highlights

▼
Market Cap: $1.70B
EBITDA: $-312.88M
Book Value: $8.63
Earnings/Share: $-4.51
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -22.73%
ROE (TTM): -36.90%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $749.02M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 129.64M
Shares Float: 58.48M
% Insiders: 8.91%
% Institutions: 90.45%
Short % Float: 6.41%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Gross Profit
subtotal
$0.00
SG&A
adjust
$-49.23M
R&D
adjust
$-109.11M
Operating Income
subtotal
$-158.34M
Other / Non-Operating Items
adjust
$9.39M
Net Income
subtotal
$-148.96M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about KLRA.US!